Runben Biotechnology released its performance for the first half of the year, with a net profit attributable to the parent company of 188 million yuan, an increase of 4.16%

According to the Zhitong Finance APP, Runben Biotechnology (603193.SH) released its semi-annual report for 2025, with operating revenue of 895 million yuan, a year-on-year increase of 20.31%. The net profit attributable to shareholders of the listed company was 188 million yuan, a year-on-year increase of 4.16%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 177 million yuan, a year-on-year increase of 0.86%. The basic earnings per share were 0.46 yuan.

In the first half of 2025, the company adhered to an integrated strategy of research, production, and sales, further expanding offline channels based on solidifying and consolidating the advantages of online channels. In response to the summer skincare needs of infants, children, and teenagers, the company launched more sunscreen products. For care products, the target audience was expanded from infants and children to teenagers, introducing an oil control and acne removal series specifically for teenage skin conditions, further enriching the product matrix. The company's brand value has further increased, and operating performance has steadily grown.

In addition, it is proposed to distribute a cash dividend of 2.00 yuan (including tax) for every 10 shares to all shareholders